Merit Medical Systems (MMSI)
(Delayed Data from NSDQ)
$94.35 USD
+0.59 (0.63%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $94.34 -0.01 (-0.01%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth D Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$94.35 USD
+0.59 (0.63%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $94.34 -0.01 (-0.01%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth D Momentum C VGM
Zacks News
Merit Medical (MMSI) Completes Cianna Medical Acquisition
by Zacks Equity Research
Merit Medical (MMSI) is likely to gain traction in the global breast lesion localization market, courtesy of the Cianna Medical acquisition.
GNC Holdings (GNC) Q3 Earnings Miss on Soft U.S. Retail
by Zacks Equity Research
GNC Holdings (GNC) discourages with sluggish domestic retail comps. However, it delivers a strong performance in e-commerce business as well as at International segment.
Phibro Animal (PAHC) Q1 Earnings Lag Estimates, Sales Up Y/Y
by Zacks Equity Research
Within Animal Health business of Phirbo Animal (PAHC), reduced selling prices across certain countries partially offset its international volume growth.
OPKO Health (OPK) Incurs Loss in Q3, Lags Revenue Estimates
by Zacks Equity Research
OPKO Health (OPK) gains from robust demand for its flagship RAYALDEE in Q3; adjusted gross margin remains pressed.
Haemonetics (HAE) Earnings & Revenues Beat Estimates in Q2
by Zacks Equity Research
Haemonetics' (HAE) year-over-year growth in Q2 is backed by benefits from complexity reduction and investments along with strength in market demand and success from early launches.
athenahealth (ATHN) Q3 Earnings Beat, Bookings Down Y/Y
by Zacks Equity Research
athenahealth's (ATHN) Business and Services unit sees a strong Q3; 2018 guidance maintained.
DexCom (DXCM) Beats Q3 Earnings Estimates, Raises '18 View
by Zacks Equity Research
Solid contribution from the Sensor, Transmitter and Receiver segments drives DexCom's (DXCM) Q3 results.
Can Canadian Market Drive Canopy Growth (CGC) Q2 Earnings?
by Zacks Equity Research
Canopy Growth (CGC) is poised to gain from continued strength in the Canadian medical cannabis market in the fiscal second quarter.
DENTSPLY SIRONA (XRAY) Q3 Earnings & Revenues Miss Estimates
by Zacks Equity Research
DENTSPLY SIRONA (XRAY) witnesses dismal segmental performance in Q3; 2018 guidance lowered.
BioScrip (BIOS) Q3 Loss Wider Than Expected, Revenues Beat
by Zacks Equity Research
A shift in BioScrip's (BIOS) strategy to focus on growing its core revenue mix plus contract changes with the UnitedHealthcare dent the company's revenue rise in Q3.
Wright Medical (WMGI) Reports Q3 Loss, Raises '18 Guidance
by Zacks Equity Research
Growth in the upper and the lower extremity segments drives Wright Medical's (WMGI) Q3 results
Inogen (INGN) Q3 Earnings Beat, 2018 Revenue Guidance Up
by Zacks Equity Research
Inogen (INGN) gains from solid direct-to-consumer revenues in Q3; 2018 view up.
Genomic Health (GHDX) Q3 Earnings and Revenues Top Estimates
by Zacks Equity Research
We are encouraged by the year-over-year rise in Genomic Health's (GHDX) revenues in Q3, driven by solid performances in the United States and internationally.
DaVita's (DVA) Q3 Earnings Lag Estimates, Kidney Care Down
by Zacks Equity Research
DaVita (DVA) gains from dialysis services in Q3; 2018 guidance narrowed.
Hologic (HOLX) Q4 Earnings Miss, Revenues Top Estimates
by Zacks Equity Research
Tough year-over-year comparisons and soft Diagnostics sales hurt Hologic's (HOLX) performance in Q4.
Myriad Genetics (MYGN) Beats on Earnings in Q1, Revenues Lag
by Zacks Equity Research
Myriad Genetics (MYGN) witnesses strong performance by GeneSight, EndoPredict, and Prolaris tests in Q1.
Cardinal Health (CAH) Surpasses Earnings Estimates in Q1
by Nabaparna Bhattacharya
Cardinal Health (CAH) Q1 results benefit from strong sales in the Pharmaceutical and the Medical segments.
STERIS (STE) Q2 Earnings & Revenues Beat Estimates, Rise Y/Y
by Zacks Equity Research
STERIS (STE) continues to gain from strength in all business segments in Q2.
Luminex's (LMNX) Q3 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Luminex (LMNX) gains from segmental contributions in Q3; margins contract.
CVS Health's (CVS) Q3 Earnings Top Estimate, Gross Margin Up
by Zacks Equity Research
CVS Health's (CVS) year-over-year growth in the top line was driven by a strong Pharmacy Services segment, benefiting from the upside in the specialty services.
Becton, Dickinson (BDX) Q4 Earnings Beat, FY19 View Strong
by Zacks Equity Research
Becton, Dickinson (BDX) gains from solid segmental contributions in Q4; fiscal 2019 guidance solid.
AmerisourceBergen (ABC) Beats on Q4 Earnings, Issues '19 View
by Zacks Equity Research
AmerisourceBergen (ABC) registers strong growth in the Pharmaceutical Distribution segment and the World Courier business in Q4.
Henry Schein's (HSIC) Q3 Earnings Top, Revenues Lag Estimates
by Zacks Equity Research
All four of Henry Schein's (HSIC) operating segments recording year-over-year growth in Q3 encourages us.
PRA Health's (PRAH) Q3 Earnings Top, Revenues Lag Estimates
by Zacks Equity Research
PRA Health (PRAH) posts year-over-year double-digit growth in earnings, revenues and net new business in Q3. However, increasing labor-related costs in the Clinical Research wing are a concern.
CONMED (CNMD) Beats Earnings, Revenue Estimates in Q3
by Zacks Equity Research
Solid domestic and international sales drive CONMED's (CNMD) results in Q3. Also, raised sales guidance encourages.